NAM
MRNA icon

Nissay Asset Management’s Moderna MRNA Stock Holding History

Nissay Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40,639
Closed -$1.15M – 725
2025
Q1 		$1.15M Buy
40,639
+562
+1% +$19.9K 0.01% 612
2024
Q4 		$1.61M Sell
40,077
-35,678
-47% -$1.71M 0.01% 569
2024
Q3 		$5.06M Buy
75,755
+6,722
+10% +$617K 0.03% 312
2024
Q2 		$8.2M Buy
69,033
+8,015
+13% +$1.01M 0.05% 215
2024
Q1 		$6.5M Buy
61,018
+16,236
+36% +$1.64M 0.05% 251
2023
Q4 		$4.45M Buy
44,782
+4,814
+12% +$405K 0.04% 284
2023
Q3 		$4.13M Buy
39,968
+1,597
+4% +$178K 0.04% 278
2023
Q2 		$4.66M Buy
38,371
+184
+0.5% +$24.5K 0.04% 250
2023
Q1 		$5.86M Sell
38,187
-1,811
-5% -$299K 0.05% 206
2022
Q4 		$7.18M Sell
39,998
-1,057
-3% -$173K 0.07% 173
2022
Q3 		$4.86M Buy
41,055
+1,050
+3% +$159K 0.05% 220
2022
Q2 		$5.71M Sell
40,005
-6,013
-13% -$859K 0.06% 192
2022
Q1 		$7.93M Buy
46,018
+860
+2% +$145K 0.07% 169
2021
Q4 		$11.5M Buy
45,158
+4,244
+10% +$1.24M 0.09% 141
2021
Q3 		$15.7M Buy
40,914
+7,425
+22% +$2.74M 0.13% 100
2021
Q2 		$7.87M Buy
33,489
+4,877
+17% +$872K 0.07% 166
2021
Q1 		$3.75M Sell
28,612
-636
-2% -$92.2K 0.04% 279
2020
Q4 		$3.06M Buy
29,248
+1,041
+4% +$105K 0.05% 310
2020
Q3 		$2M Buy
28,207
+632
+2% +$44.1K 0.03% 361
2020
Q2 		$1.77M Buy
+27,575
New +$1.51M 0.03% 395

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Nissay Asset Management's MRNA Position: Q2 2025 in Review

Nissay Asset Management sold out of Moderna (MRNA) in Q2 2025, closing a stake of 40,639 shares — an estimated $1.15M sold.

Nissay Asset Management first reported a position in MRNA in Q2 2020 and held it in 20 quarters. The position peaked at $15.7M in Q3 2021. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Nissay Asset Management reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • Nissay Asset Management sold 40,639 Moderna shares in Q2 2025, an estimated $1.15M.
  • Nissay Asset Management first reported a position in Moderna in Q2 2020 and held it in 20 quarters.
  • Nissay Asset Management's Moderna position peaked at $15.7M in Q3 2021.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Nissay Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.